https://www.selleckchem.com/pr....oducts/cbl0137-cbl-0
Among the 130 selected studies, nine papers were included for quantitative synthesis. The quality-appraisal was good for two, fair for three and poor for four studies. The pooled relative risk (RR) of SVR12 was not statistically different between decentralized strategy and treatment by specialists [RR = 1.05; 95% confidence interval (95% CI) 0.98-1.1; I2 = 45% (95% CI 0-84%), p = 0.145]. SVR12 rate for decentralized HCV treatment was 81% [SVR12 95% CI 72-89%; I2 = 93% (95% CI 88-96%)] and 95% [SVR12 95%CI 92-98%; I2 = 77% (95%
Like
Comment
Share
